Journal of Thoracic Disease 2022 August [Link] Olivia Lauk, Thomas Neuer, Bianca Battilana, Ilhan Inci, Katarzyna Furrer, Walter Weder, Masaki Hashimoto, Isabelle Opitz Abstract Background: Malignant pleural mesothelioma (MPM) is associated with high rates of local recurrence (LR) up to 75%. Second line treatment should be applied tailored to relapse pattern. We aimed to establish…

Read More

Journal of Thoracic Oncology 2022 September 5 [Link] Michael Offin, Dilanka De Silva, Jennifer L Sauter, Jacklynn V Egger, Ellen Yorke, Prasad S Adusumilli, Andreas Rimner, Valerie W Rusch, Marjorie G Zauderer Abstract Background: Primary pericardial mesothelioma (PPM) has no accepted standard of care treatment options with management and outcomes often extrapolated from diffuse pleural…

Read More

Journal of Chest Surgery 2022 September 7 [Link] Muhammet Sayan, Aynur Bas, Merve Satir Turk, Dilvin Ozkan, Ali Celik, İsmail Cuneyt Kurul, Abdullah Irfan Tastepe Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive pleural malignancy, and despite all multimodal treatment modalities, the 5-year overall survival rate of patients with MPM is less than 20%.…

Read More

Updates in Surgery 2022 September 3 [Link] Dimitrios E Magouliotis, Prokopis-Andreas Zotos, Arian Arjomandi Rad, Despoina Koukousaki, Vasiliki Vasilaki, Ioustini Portesi, Kyriakos Spiliopoulos, Thanos Athanasiou Abstract Objective: We reviewed the available literature on patients with MPM undergoing either extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D). Methods: Original research studies that evaluated long-term outcomes of P/D versus…

Read More

Thoracic Cancer 2022 September 2 [Link] Francesco Falanga, Pietro Rinaldi, Cristiano Primiceri, Chandra Bortolotto, Olga Oneta, Francesco Agustoni, Patrizia Morbini, Laura Saracino, Dimitrios Eleftheriou, Federico Sottotetti, Giulia Maria Stella Abstract Surgery is part of a multimodal therapeutic approach to malignant pleural mesothelioma (MPM) although its real beneficial effect is still controversial. The optimal precise sequence…

Read More

Journal of Clinical Medicine 2022 August 3 [Link] Giuseppe Mangiameli, Edoardo Bottoni, Umberto Cariboni, Giorgio Maria Ferraroli, Emanuela Morenghi, Veronica Maria Giudici, Emanuele Voulaz, Marco Alloisio, Alberto Testori Abstract Objectives: We examined a series of malignant pleural mesothelioma (MPM) patients who consecutively underwent surgery in our institution during the last 20 years. Across this period,…

Read More

BioMed Research International 2022 July 27 [Link] M Shobana, V R Balasraswathi, R Radhika, Ahmed Kareem Oleiwi, Sushovan Chaudhury, Ajay S Ladkat, Mohd Naved, Abdul Wahab Rahmani Abstract Cancer of the mesothelium, sometimes referred to as malignant mesothelioma (MM), is an extremely uncommon form of the illness that almost always results in death. Chemotherapy, surgery,…

Read More

Acta Chirurgica Belgica 2022 July 15 [Link] Mehmet Ali Bedirhan, Yunus Seyrek, Volkan Yaran, Celal Buğra Sezen, Levent Cansever, Muzaffer Metin Abstract Background: This study examined the effect of metastatic mediastinal lymph node involvement on the prognosis of patients with malignant pleural mesothelioma (MPM) who underwent extrapleural pneumonectomy (EPP) or extended pleurectomy (E/P) and also…

Read More

Surgical Oncology 2022 July 6 [Link] Riki Okita, Masanori Okada, Hidetoshi Inokawa, Tomoyuki Murakami, Eiji Ikeda Abstract Introduction: A preoperative validation system for predicting the clinical outcome of extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM) is required, as EPP for MPM is one of the most invasive operation types. Recently, several inflammatory and nutritional…

Read More

International Journal of Molecular Science 2022 June 30 [Link] Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann, Chris Braumann Abstract Malignant peritoneal mesothelioma is a rare tumor entity. Although cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have increased overall survival, its prognosis remains poor. Established chemotherapeutics…

Read More